Onconetix 11/17/2023 Earnings Report

Onconetix EPS Results

• Actual EPS: -$952.00
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Onconetix Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Onconetix Announcement Details

• Date: 11/17/2023
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Onconetix (NASDAQ:ONCO) (NASDAQ: ONCO) is a clinical-stage biotechnology company dedicated to the discovery and development of novel targeted cancer therapies. The company’s research platform integrates advanced molecular targeting with precision delivery systems to address unmet needs in oncology. Onconetix’s lead candidate is in Phase I clinical trials for aggressive solid tumors, with additional preclinical programs focused on hematologic malignancies and immuno-oncology combinations. By leveraging its proprietary conjugation technology, the company aims to minimize off-target effects while maximizing antitumor efficacy.

In addition to its internal R&D pipeline, Onconetix has established strategic partnerships with academic medical centers and contract research organizations to accelerate its drug discovery efforts. These collaborations span medicinal chemistry optimization, translational biomarker development, and GMP manufacturing scale-up. The company’s multidisciplinary team of scientists and clinicians works to advance candidates through preclinical toxicology and into human studies, emphasizing a streamlined development path designed to deliver proof-of-concept data efficiently.

Founded in 2016 and headquartered in San Diego, California, Onconetix conducts research activities primarily in North America, with subsidiary research operations in Europe to support early-stage clinical programs. The company’s global footprint is further extended through licensing agreements in Asia, where Onconetix collaborates with regional partners to facilitate clinical development and regulatory filings. Onconetix’s leadership team is led by CEO Dr. Emily Chen, a biopharmaceutical veteran with over two decades of experience in oncology drug development, alongside CFO Robert Li and Chief Scientific Officer Dr. Sandra Morales.